GLOBAL biopharmaceutical company Alexion, which specialises in life-threatening diseases with little or no effective treatments, has announced 2Q17 total revenues of US$912 million, 21% up over 2Q16, in its NASDAQ report to shareholders.
The company said it was increasing 2017 revenue guidance to $3.450 - $3.525 billion.
The negative impact of foreign currency on total revenue year-over-year was 2% or $12 million, net of hedging activities.
Diluted earnings per share (EPS) in the quarter was $0.73 per share, compared to $0.53 per share in the second quarter of 2016.
Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa) drove the impressive business growth.
Go to news.alexionpharma.com.
The above article was sent to subscribers in Pharmacy Daily's issue from 01 Aug 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 01 Aug 17
